Participant has a primary diagnosis of schizophrenia
Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization.
Participants taking prohibited medications, including antipsychotics, must discontinue before study participation
Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements
You may not be if
Participant has known hypersensitivity to any component of the formulation of NBI-1117568.
Participant has an unstable or poorly controlled medical condition or chronic disease
Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others
Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening
Participant has a positive alcohol test or drug screen for disallowed substances
Participants have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Clareo Health | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
